Baltimore, MD10 Active Studies

Breast Cancer Clinical Trials in Baltimore, MD

Find 10 actively recruiting breast cancer clinical trials in Baltimore, MD. Connect with local research sites and explore new treatment options.

10
Active Trials
9
Sponsors
4,431
Enrolling

Recruiting Breast Cancer Studies in Baltimore

RecruitingBaltimore, MDNCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Earl...

2,400 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBaltimore, MDNCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

1,000 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBaltimore, MDNCT05696626

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- ...

500 participants
Sermonix Pharmaceuticals Inc.
View Study Details
RecruitingBaltimore, MDNCT03971409

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating pat...

150 participants
Laura Huppert, MD, BA
View Study Details
RecruitingBaltimore, MDNCT01766297

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will ...

132 participants
Proton Collaborative Group
View Study Details
RecruitingBaltimore, MDNCT06568692

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metas...

90 participants
Processa Pharmaceuticals
View Study Details
RecruitingBaltimore, MDNCT03858153

Exercise and Nutrition Interventions During Chemotherapy K07

Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of taxane chemotherapy, often used to treat breast cancer. Unfortunately there are very limited treatment...

80 participants
University of Rochester
View Study Details
RecruitingBaltimore, MDNCT05455658

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system ...

33 participants
University of Washington
View Study Details
RecruitingBaltimore, MDNCT06245889

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after...

30 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details
RecruitingBaltimore, MDNCT02422641

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Management of leptomeningeal disease (LMD) in patients with metastatic breast cancer is an area of unmet clinical need. High-dose methotrexate (HD-MTX) is known to have activity against breast cancer ...

16 participants
Wake Forest University Health Sciences
View Study Details

About Breast Cancer Clinical Trials in Baltimore

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 10 breast cancer clinical trials recruiting participants in Baltimore, MD. These studies are seeking a combined 4,431 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Sermonix Pharmaceuticals Inc., Laura Huppert, MD, BA and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Baltimore — FAQ

Are there breast cancer clinical trials in Baltimore?

Yes, there are 10 breast cancer clinical trials currently recruiting in Baltimore, MD. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Baltimore?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Baltimore research site will contact you about next steps.

Are clinical trials in Baltimore free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Baltimore studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 10 active trials in Baltimore are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated March 2, 2026 from ClinicalTrials.gov